share_log

Chardan Capital Maintains Buy on EyePoint Pharmaceuticals, Lowers Price Target to $28

Chardan Capital Maintains Buy on EyePoint Pharmaceuticals, Lowers Price Target to $28

Chardan Capital维持对EyePoint制药的买入,将目标股价下调至28美元
Benzinga ·  05/07 08:51

Chardan Capital analyst Daniil Gataulin maintains EyePoint Pharmaceuticals (NASDAQ:EYPT) with a Buy and lowers the price target from $39 to $28.

查尔丹资本分析师丹尼尔·加陶林维持EyePoint Pharmicals(纳斯达克股票代码:EYPT)的买入并将目标股价从39美元下调至28美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发